Robert T. Heelan

12.3k total citations · 3 hit papers
78 papers, 9.7k citations indexed

About

Robert T. Heelan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Robert T. Heelan has authored 78 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 15 papers in Surgery. Recurrent topics in Robert T. Heelan's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (21 papers) and Lung Cancer Research Studies (19 papers). Robert T. Heelan is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (21 papers) and Lung Cancer Research Studies (19 papers). Robert T. Heelan collaborates with scholars based in United States, South Africa and Russia. Robert T. Heelan's co-authors include Mark G. Kris, Vincent A. Miller, Maureen F. Zakowski, William Pao, Valerie W. Rusch, Harold Varmus, Bhuvanesh Singh, Doris M. Kupfer, Lucinda A. Fulton and Richard K. Wilson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer.

In The Last Decade

Robert T. Heelan

77 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 3.5k citations William Pao, Vincent A. Miller et al. profile →
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 1.2k citations William Pao, Gregory J. Riely et al. PLoS Medicine profile →
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

2004 628 citations Vincent A. Miller, Mark G. Kris et al. profile →

Peers

Robert T. Heelan

PRM

ONCOL

MB

CR

RNMI

Michelle S. Ginsberg United States

Christian Manegold Germany

Maciej Krzakowski Poland

A Płużańska Poland

Sanja Đačić United States

Steven D. Averbuch United States

Hidefumi Sasaki Japan

David Olmos United Kingdom

I. Bodrogi Hungary

U. Gatzemeier Germany

Michelle S. Ginsberg United States

Robert T. Heelan

6.0k ×0.8

PRM

3.5k ×0.6

ONCOL

3.3k ×1.3

MB

2.1k ×1.4

CR

1.8k ×1.8

RNMI

Citations per year, relative to Robert T. Heelan Robert T. Heelan (= 1×) peers Michelle S. Ginsberg

Countries citing papers authored by Robert T. Heelan

Since Specialization

Citations

This map shows the geographic impact of Robert T. Heelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert T. Heelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert T. Heelan more than expected).

Fields of papers citing papers by Robert T. Heelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert T. Heelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert T. Heelan. The network helps show where Robert T. Heelan may publish in the future.

Co-authorship network of co-authors of Robert T. Heelan

This figure shows the co-authorship network connecting the top 25 collaborators of Robert T. Heelan. A scholar is included among the top collaborators of Robert T. Heelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert T. Heelan. Robert T. Heelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Feinstein, Marc B., André L. Moreira, Diane E. Stover, et al.. (2015). A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. Journal of Clinical Pathology. 68(6). 441–447. 34 indexed citations

2.

Price, Katharine A., Christopher G. Azzoli, Lee M. Krug, et al.. (2010). Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(10). 1623–1629. 74 indexed citations

3.

Krug, Lee M., Robert T. Heelan, Mark G. Kris, Ennapadam Venkatraman, & F. M. Sirotnak. (2007). Phase II Trial of Pralatrexate (10-Propargyl-10-deazaaminopterin, PDX) in Patients with Unresectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2(4). 317–320. 18 indexed citations

4.

Kris, Mark G., William Pao, Maureen F. Zakowski, et al.. (2007). D2-01: Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib. Journal of Thoracic Oncology. 2(8). S393–S393. 1 indexed citations

5.

Ginsberg, Michelle S., Ravinder K. Grewal, & Robert T. Heelan. (2007). Lung Cancer. Radiologic Clinics of North America. 45(1). 21–43. 53 indexed citations

6.

Flores, Raja M., Lee M. Krug, Kenneth E. Rosenzweig, et al.. (2006). Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial. Journal of Thoracic Oncology. 1(4). 289–295. 115 indexed citations

7.

Pao, William, Gregory J. Riely, Vincent A. Miller, et al.. (2005). KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Medicine. 2(1). e17–e17. 1228 indexed citations breakdown →

8.

Reed, Carolyn E., David H. Harpole, Katherine E. Posther, et al.. (2003). Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 126(6). 1943–1951. 199 indexed citations

9.

Yankelevitz, David F., William J. Kostis, Claudia I. Henschke, et al.. (2003). Overdiagnosis in chest radiographic screening for lung carcinoma. Cancer. 97(5). 1271–1275. 86 indexed citations

10.

Downey, Robert J., Kenneth Ng, Mark G. Kris, et al.. (2002). A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer. 38(2). 193–197. 76 indexed citations

11.

Kronawitter, Ursula, Nancy E. Kemeny, Robert T. Heelan, Farid Fata, & Yuman Fong. (1999). Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer. 86(2). 229–235.

12.

Kronawitter, Ursula, Nancy E. Kemeny, Robert T. Heelan, Farid Fata, & Yuman Fong. (1999). Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer. 86(2). 229–235. 58 indexed citations

13.

Heelan, Robert T., David M. Panicek, Michael Burt, et al.. (1997). Magnetic Resonance Imaging of the Postpneumonectomy Chest. Journal of Thoracic Imaging. 12(3). 200–208. 9 indexed citations

14.

Miller, Vincent A., James R. Rigas, Prudence A. Francis, et al.. (1995). Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75(4). 968–972. 104 indexed citations

15.

Heelan, Robert T.. (1994). CT AND MR IMAGING IN THE EVALUATION OF PLEURAL MASSES. Chest Surgery Clinics of North America. 4(3). 431–450. 2 indexed citations

16.

Casper, Ephraim S., Mark R. Green, David P. Kelsen, et al.. (1994). Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investigational New Drugs. 12(1). 29–34. 372 indexed citations

17.

Rusch, Valerie W., Homer A. Macapinlac, Robert T. Heelan, et al.. (1993). NR-LU-10 monoclonal antibody scanning. Journal of Thoracic and Cardiovascular Surgery. 106(2). 200–204. 19 indexed citations

18.

Bajorin, Dean F., Paul B. Chapman, David Lovett, et al.. (1991). A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer. 68(6). 1230–1237. 20 indexed citations

19.

Frame, James D., et al.. (1988). A Phase II Trial of Streptozotocin and Adriamycin in Advanced APUD Tumors. American Journal of Clinical Oncology. 11(4). 490–495. 27 indexed citations

20.

Martini, Nael, Robert T. Heelan, Manjit S. Bains, et al.. (1985). Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma. Journal of Thoracic and Cardiovascular Surgery. 90(5). 639–648. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact